Drug Innovation and Government-Operated Health Systems

<p style="line-height: 19.0400009155273px;"><span style="line-height: 19.0400009155273px;">On August 30, 2014, cardiovascular drug researchers managing the PARADIGM-HF Study and its Committees announced that they were terminating their Phase III trial of LCZ696 because of observed “<a href="http://www.dailymail.co.uk/health/article-2738993/Remarkable-new-heart-drug-cut-deaths-fifth-available-early-year.html">overwhelming benefit</a>.” As reported in The Daily Mail: “Thousands of lives could be saved by a new drug for heart failure that researchers claim outperforms the current best treatments. … Research on more than 8,000 patients found that it saved 20 per cent more lives than the current ‘gold standard’ treatment – the ACE inhibitor enalapril.” The <a href="http://www.reuters.com/article/2014/08/30/us-health-heart-novartis-idUSKBN0GU0CQ20140830">findings were announced</a> at the annual meeting of the European Society of Cardiology and published the same day in the <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1409077">The New England Journal of Medicine</a>. In a news release, the Switzerland-based Novartis International AG – the drug manufacturer sponsor – said that it would submit an FDA application to market the drug in the US by the end of 2014. Novartis anticipates <a href="http://www.novartis.com/newsroom/media-releases/en/201...
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Health Care Pharmaceuticals Distributive Justice drug safety syndicated Source Type: blogs